Blood-pressure-lowering peptide (IPPVPP)
A small peptide that blocks ACE, the enzyme that raises blood pressure, helping to lower it; used only as a lab research tool.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Does your gut need to break this peptide apart before it can actually lower blood pressure?
If true, swallowing IPPVPP could be a more reliable way to deliver IPP, a smaller peptide already shown in clinical trials to reduce blood pressure, because the larger version might survive digestion better before releasing its active piece. This could matter for people using food-based supplements to manage mild hypertension.
Could a single chemical swap stop the body from destroying this peptide too fast to do any good?
Peptides taken by mouth are often chewed up by digestive enzymes before they can act. If flipping just one building block at the start of the chain blocks that breakdown, IPPVPP could stay active long enough to actually lower blood pressure, which would be an important step toward turning it into a practical supplement or drug candidate.
Does this peptide work differently from standard blood pressure drugs, and could that make it safer?
Common ACE-inhibitor drugs latch onto the zinc atom inside the enzyme, which sometimes causes side effects like a persistent cough or kidney stress. If IPPVPP works by simply fitting into the enzyme's slot instead, it might reduce blood pressure with fewer of those side effects. This would help explain why it appears safer in early data, though direct clinical confirmation is still needed.
Could someone with normal blood pressure take this without worrying it will push their pressure too low?
One serious risk with prescription blood-pressure drugs is that they can cause dangerous drops in people who do not need them. If IPPVPP turns out to be too mild to override the body's own regulation when pressure is already normal, it could be used in foods or supplements without that risk, making it a safer option for the many people with borderline or diet-managed hypertension.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.6979984045028687 | boltz-2 |
| ranking score | 0.8373614549636841 | boltz-2 |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 1.356 | global PDE — lower = better |
| disorder | NaN | fraction disordered |
▸3-letter notation
▸recipeboltz-2 1.0
| parameter | value |
|---|---|
| model | boltz-2 1.0 |
| weights | — |
| hardware | nvidia_nim_api |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | none |
| diffusion samples | 1 |
| runtime | — |
| predicted by | mlx@peptide |
| predicted at | 2026-04-24 |
▸citationbibtex
@peptide{pep04920,
sequence = {IPPVPP},
target = {ace},
author = {peptidemodel},
year = {2026},
status = {computed}
}